ISG15 in the tumorigenesis and treatment of cancer: An emerging role in malignancies of the digestive system

Oncotarget

Volumn 7, Issue 45, 2016, Pages 74393-74409

  Zuo, Chaohui ^a,b   Sheng, Xinyi ^b   Ma, Min ^a   Xia, Man ^c   Ouyang, Linda ^c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

^c Cancer Hospital of Hunan Province   (China)

Author keywords

Cancer; Digestive system; Interferon; Interferon stimulated gene 15; Tumorigenesis

Indexed keywords

CAMPTOTHECIN; CELL PROTEIN; DECITABINE; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; INTERFERON; INTERFERON STIMULATED GENE 15 UBIQUITIN LIKE MODIFIER PROTEIN; IRINOTECAN; UNCLASSIFIED DRUG; CYTOKINE; ISG15 PROTEIN, HUMAN; UBIQUITIN;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG SENSITIVITY; ESOPHAGUS CANCER; HUMAN; INNATE IMMUNITY; LIVER CANCER; LUNG CANCER; METASTASIS; MICROARRAY ANALYSIS; NONHUMAN; PANCREAS CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TRANSCRIPTOMICS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; UBIQUITINATION; AMINO ACID SEQUENCE; ANIMAL; GASTROINTESTINAL TUMOR; METABOLISM;

AMINO ACID SEQUENCE; ANIMALS; CARCINOGENESIS; CYTOKINES; GASTROINTESTINAL NEOPLASMS; HUMANS; UBIQUITINS;

EID: 84995767791     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11911     Document Type: Review

References (165)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA. 2015; 65: 5-29. doi: 10.3322/caac.21254.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA. 2015; 65: 87-108.
3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA. 2016; 66: 115-132. doi:
4. Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C, Loi S. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clinical cancer research. 2013; 19: 28-33.
5. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature medicine. 2007; 13: 1050-1059.
6. Galluzzi L, Maiuri M, Vitale I, Zischka H, Castedo M, Zitvogel L, Kroemer G. Cell death modalities: classification and pathophysiological implications. Cell death and differentiation. 2007; 14: 1237-1242.
7. Niewerth D, Kaspers G, Assaraf YG, van Meerloo J, Kirk CJ, Anderl J, Blank JL, Van de Ven PM, Zweegman S, Jansen G. Interferon-gamma-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines. J Hematol Oncol. 2014; 7: 7.
8. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. Journal of the National Cancer Institute. 2013: djs629.
9. Pang KR, Wu JJ, Huang DB, Tyring SK, Baron S. Biological and clinical basis for molecular studies of interferons. Methods Mol Med. 2005; 116: 1-23. doi: 10.1385/1-59259-939-7:1.
10. Durante M, Reppingen N, Held KD. Immunologically augmented cancer treatment using modern radiotherapy. Trends in molecular medicine. 2013; 19: 565-582. doi:
11. Kirkwood J. (2002). Cancer immunotherapy: the interferon-a experience. Seminars in oncology: Elsevier), pp. 18-26.
12. Barker CA, Postow MA. Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. International Journal of Radiation Oncology* Biology* Physics. 2014; 88: 986-997.
13. Rocha F, Hashimoto Y, Traverso L, Dorer R, Kozarek R, Helton W, Picozzi V. Interferon-based Adjuvant Chemoradiation for Resected Pancreatic Head Cancer: Long-term Follow-up of the Virginia Mason Protocol. Annals of surgery. 2016; 263: 376.
14. Xu K, Lee F, Gao SJ, Chung JE, Yano H, Kurisawa M. Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-a2a for liver cancer therapy. Journal of Controlled Release. 2013; 166: 203-210.
15. Rossi EA, Rossi DL, Cardillo TM, Chang C-H, Goldenberg DM. Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2-Bispecific Antibody Is Enhanced in Combination with Interferon-a. Molecular cancer therapeutics. 2014; 13: 2341-2351.
16. Cunningham CR, Champhekar A, Tullius MV, Dillon BJ, Zhen A, de la Fuente JR, Herskovitz J, Elsaesser H, Snell LM, Wilson EB, de la Torre JC, Kitchen SG, Horwitz MA, et al. Type I and Type II Interferon Coordinately Regulate Suppressive Dendritic Cell Fate and Function during Viral Persistence. PLoS Pathog. 2016; 12: e1005356. doi: 10.1371/journal.ppat.1005356.
17. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008; 8: 559-568. doi: 10.1038/nri2314.
18. Reich N, Evans B, Levy D, Fahey D, Knight E, Darnell J. Interferon-induced transcription of a gene encoding a 15-kDa protein depends on an upstream enhancer element. Proceedings of the National Academy of Sciences. 1987; 84: 6394-6398.
19. Durfee LA, Huibregtse JM. The ISG15 conjugation system. Methods Mol Biol. 2012; 832: 141-149. doi: 10.1007/978-1-61779-474-2_9.
20. Cajee UF, Hull R, Ntwasa M. Modification by ubiquitinlike proteins: significance in apoptosis and autophagy pathways. Int J Mol Sci. 2012; 13: 11804-11831. doi: 10.3390/ijms130911804.
21. Darb-Esfahani S, Sinn BV, Rudl M, Sehouli J, Braicu I, Dietel M, Denkert C. Interferon-stimulated gene, 15 kDa (ISG15) in ovarian high-grade serous carcinoma: prognostic impact and link to NF-kappaB pathway. Int J Gynecol Pathol. 2014; 33: 16-22. doi: 10.1097/PGP.0b013e31827b25a2.
22. Wood LM, Pan ZK, Seavey MM, Muthukumaran G, Paterson Y. The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy. Cancer Immunol Immunother. 2012; 61: 689-700. doi: 10.1007/s00262-011-1129-9.
23. Desai SD, Reed RE, Burks J, Wood LM, Pullikuth AK, Haas AL, Liu LF, Breslin JW, Meiners S, Sankar S. ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells. Exp Biol Med (Maywood). 2012; 237: 38-49. doi: 10.1258/ebm.2011.011236.
24. Hadjivasiliou A. ISG15 implicated in cytoskeleton disruption and promotion of breast cancer. Expert Rev Proteomics. 2012; 9: 7.
25. Vincent-Chong VK, Ismail SM, Rahman ZA, Sharifah NA, Anwar A, Pradeep PJ, Ramanathan A, Karen-Ng LP, Kallarakkal TG, Mustafa WM, Abraham MT, Tay KK, Zain RB. Genome-wide analysis of oral squamous cell carcinomas revealed over expression of ISG15, Nestin and WNT11. Oral Dis. 2012; 18: 469-476. doi: 10.1111/j.1601-0825.2011.01894.x.
26. Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D. Global cancer statistics. CA. 2011; 61: 69.
27. Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nature Reviews Cancer. 2016; 16: 131-144.
28. Uze G, Schreiber G, Piehler J, Pellegrini S. (2007). The receptor of the type I interferon family. Interferon: The 50th Anniversary: Springer), pp. 71-95.
29. LaFleur DW, Nardelli B, Tsareva T, Mather D, Feng P, Semenuk M, Taylor K, Buergin M, Chinchilla D, Roshke V. Interferon-?, a novel type I interferon expressed in human keratinocytes. Journal of Biological Chemistry. 2001; 276: 39765-39771.
30. Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A, Lee C, Yarden G, Vleck SE, Glenn JS. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell. 2011; 146: 621-632.
31. Fung KY, Mangan NE, Cumming H, Horvat JC, Mayall JR, Stifter SA, De Weerd N, Roisman LC, Rossjohn J, Robertson SA. Interferon-e protects the female reproductive tract from viral and bacterial infection. Science. 2013; 339: 1088-1092.
32. Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. J Hepatol. 2014; 61: S14-25. doi: 10.1016/j.jhep.2014.06.035.
33. Luszczek W, Cheriyath V, Mekhail T, Borden E. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFNstimulated gene expression. Molecular cancer therapeutics. 2010; 9: 2309.
34. Cheon H, Yang J, Stark GR. The Functions of Signal Transducers and Activators of Transcriptions 1 and 3 as Cytokine-Inducible Proteins. Journal of Interferon & Cytokine Research. 2011; 31: 33.
35. Platanias L. Mechanisms of type-I-and type-II-interferonmediated signalling. Nature reviews Immunology. 2005; 5: 375.
36. Uddin S, Yenush L, Sun X, Sweet M, White M, Platanias L. Interferon-alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3'-kinase. The Journal of biological chemistry. 1995; 270: 15938.
37. Durbin RK, Kotenko SV, Durbin JE. Interferon induction and function at the mucosal surface. Immunol Rev. 2013; 255: 25-39. doi: 10.1111/imr.12101.
38. Herzer K, Hofmann TG, Teufel A, Schimanski CC, Moehler M, Kanzler S, Schulze-Bergkamen H, Galle PR. IFN-alphainduced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res. 2009; 69: 855-862. doi: 10.1158/0008-5472.CAN-08-2831.
39. Zuo C, Xia M, Wu Q, Zhu H, Liu J, Liu C. Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review). Oncol Lett. 2015; 9: 527-534. doi: 10.3892/ol.2014.2727.
40. Schweizer M, Matzener P, Pfaffen G, Stalder H, Peterhans E. "Self" and "nonself" manipulation of interferon defense during persistent infection: bovine viral diarrhea virus resists alpha/beta interferon without blocking antiviral activity against unrelated viruses replicating in its host cells. J Virol. 2006; 80: 6926-6935. doi: 10.1128/JVI.02443-05.
41. Wilden H, Schirrmacher V, Fournier P. Important role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus. Int J Oncol. 2011; 39: 493-504. doi: 10.3892/ijo.2011.1033.
42. Liu Y, Lou G, Wu W, Shi Y, Zheng M, Chen Z. Interferon-a sensitizes HBx-expressing hepatocarcinoma cells to chemotherapeutic drugs through inhibition of HBxmediated NF-?B activation. Virology journal. 2013; 10: 1.
43. Wang S, El-Deiry W. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene. 2003; 22: 8628.
44. Zuo CH, Xia M, Liu JS, Qiu XX, Lei X, Xu RC, Liu HC, Li JL, Li YG, Li QL, Xiao H, Hong Y, Wang XH, et al. Transcatheter arterial chemoembolization combined with interferon-alpha is safe and effective for patients with hepatocellular carcinoma after curative resection. Asian Pac J Cancer Prev. 2015; 16: 245-251.
45. Heldin C-H. Dimerization of cell surface receptors in signal transduction. Cell. 1995; 80: 213-223.
46. Zhang SY, Boisson-Dupuis S, Chapgier A, Yang K, Bustamante J, Puel A, Picard C, Abel L, Jouanguy E, Casanova JL. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev. 2008; 226: 29-40. doi: 10.1111/j.1600-065X.2008.00698.x.
47. Colonna M. TLR pathways and IFN-regulatory factors: to each its own. Eur J Immunol. 2007; 37: 306-309. doi: 10.1002/eji.200637009.
48. Ginter T, Bier C, Knauer SK, Sughra K, Hildebrand D, Münz T, Liebe T, Heller R, Henke A, Stauber RH. Histone deacetylase inhibitors block IFN?-induced STAT1 phosphorylation. Cellular signalling. 2012; 24: 1453-1460.
49. Schroder K, Hertzog P, Ravasi T, Hume D. Interferongamma: an overview of signals, mechanisms and functions. Journal of leukocyte biology. 2004; 75: 163.
50. Slattery ML, Lundgreen A, Bondurant KL, Wolff RK. Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis. 2011: bgr189.
51. Bosek I, Kuczerowski R, Milek T, Sulich A, Kaleta B. Evaluation of Interferon-Gamma in Patients with Type 2 Diabetes and Colorectal Cancer. J Diabetes Metab. 2016; 6: 2.
52. Wang L, Wang Y, Song Z, Chu J, Qu X. Deficiency of Interferon-Gamma or Its Receptor Promotes Colorectal Cancer Development. Journal of Interferon & Cytokine Research. 2015; 35: 273-280.
53. Gerber SA, Sedlacek AL, Cron KR, Murphy SP, Frelinger JG, Lord EM. IFN-γ Mediates the Antitumor Effects of Radiation Therapy in a Murine Colon Tumor. The American Journal of Pathology. 2013; 182: 2345-2354.
54. Li P, Du Q, Cao Z, Guo Z, Evankovich J, Yan W, Chang Y, Shao L, Stolz DB, Tsung A. Interferon-gamma induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon regulatory factor-1 (IRF-1). Cancer letters. 2012; 314: 213-222.
55. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. IFN-?s mediate antiviral protection through a distinct class II cytokine receptor complex. Nature immunology. 2003; 4: 69-77.
56. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nature immunology. 2003; 4: 63-68.
57. Fox BA, Sheppard PO, O'Hara PJ. The role of genomic data in the discovery, annotation and evolutionary interpretation of the interferon-lambda family. PloS one. 2009; 4: e4933.
58. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nature genetics. 2013; 45: 164-171.
59. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharmacol Ther. 2012; 135: 44-53. doi: 10.1016/j. pharmthera.2012.03.006.
60. Bolen CR, Ding S, Robek MD, Kleinstein SH. Dynamic expression profiling of type I and type III interferonstimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology. 2014; 59: 1262-1272.
61. Sommereyns C, Paul S, Staeheli P, Michiels T. IFNlambda (IFN-?) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 2008; 4: e1000017.
62. Blomstrom DC, Fahey D, Kutny R, Korant BD, Knight E. Molecular characterization of the interferon-induced 15-kDa protein. Molecular cloning and nucleotide and amino acid sequence. Journal of Biological Chemistry. 1986; 261: 8811-8816.
63. Jinawath N, Furukawa Y, Hasegawa S, Li M, Tsunoda T, Satoh S, Yamaguchi T, Imamura H, Inoue M, Shiozaki H. Comparison of gene-expression profiles between diffuseand intestinal-type gastric cancers using a genome-wide cDNA microarray. Oncogene. 2004; 23: 6830.
64. Ritchie KJ, Zhang D-E. (2004). ISG15: the immunological kin of ubiquitin. Seminars in cell & developmental biology: Elsevier), pp. 237-246.
65. Jeon Y, Yoo H, Chung C. ISG15 and immune diseases. Biochimica et biophysica acta. 2010; 1802: 485.
66. Kerscher O, Felberbaum R, Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol. 2006; 22: 159-180.
67. Langevin C, van der Aa LM, Houel A, Torhy C, Briolat V, Lunazzi A, Harmache A, Bremont M, Levraud JP, Boudinot P. Zebrafish ISG15 exerts a strong antiviral activity against RNA and DNA viruses and regulates the interferon response. J Virol. 2013; 87: 10025-10036. doi: 10.1128/JVI.01294-12.
68. Chen L, Li S, McGilvray I. The ISG15/USP18 ubiquitinlike pathway (ISGylation system) in hepatitis C virus infection and resistance to interferon therapy. Int J Biochem Cell Biol. 2011; 43: 1427-1431. doi: 10.1016/j. biocel.2011.06.006.
69. Herrmann J, Lerman LO, Lerman A. Ubiquitin and ubiquitin-like proteins in protein regulation. Circulation research. 2007; 100: 1276-1291.
70. Pickart C. Mechanisms underlying ubiquitination. Annual review of biochemistry. 2001; 70: 503.
71. Narasimhan J, Potter J, Haas A. Conjugation of the 15-kDa interferon-induced ubiquitin homolog is distinct from that of ubiquitin. The Journal of biological chemistry. 1996; 271: 324.
72. Kok K, Hofstra R, Pilz A, van den Berg A, Terpstra P, Buys C, Carritt B. A gene in the chromosomal region 3p21 with greatly reduced expression in lung cancer is similar to the gene for ubiquitin-activating enzyme. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90: 6071.
73. Inoue S, Orimo A, Matsuda Y, Inazawa J, Emi M, Nakamura Y, Hori T, Muramatsu M. Chromosome mapping of human (ZNF147) and mouse genes for estrogenresponsive finger protein (efp), a member of the RING finger family. Genomics. 1995; 25: 581.
74. Spratt DE, Walden H, Shaw GS. RBR E3 ubiquitin ligases: new structures, new insights, new questions. Biochemical Journal. 2014; 458: 421.
75. Mitsui K, Nakanishi M, Ohtsuka S, Norwood T, Okabayashi K, Miyamoto C, Tanaka K, Yoshimura A, Ohtsubo M. A novel human gene encoding HECT domain and RCC1-like repeats interacts with cyclins and is potentially regulated by the tumor suppressor proteins. Biochemical and biophysical research communications. 1999; 266: 115.
76. Malakhov M, Malakhova O, Kim K, Ritchie K, Zhang D. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. The Journal of biological chemistry. 2002; 277: 9976.
77. Lenschow DJ. Antiviral Properties of ISG15. Viruses. 2010; 2: 2154.
78. Bogunovic D, Boisson-Dupuis S, Casanova J-L. ISG15: leading a double life as a secreted molecule. Experimental & molecular medicine. 2013; 45: e18.
79. Yuan W, Krug RM. Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. The EMBO Journal. 2001; 20: 362.
80. Bogunovic D, Byun M, Durfee LA, Abhyankar A, Sanal O, Mansouri D, Salem S, Radovanovic I, Grant AV, Adimi P, Mansouri N, Okada S, Bryant VL, et al. Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited ISG15 deficiency. Science. 2012; 337: 1684-1688. doi: 10.1126/science.1224026.
81. D'Cunha J, Knight E, Jr., Haas AL, Truitt RL, Borden EC. Immunoregulatory properties of ISG15, an interferoninduced cytokine. Proc Natl Acad Sci U S A. 1996; 93: 211-215.
82. D'Cunha J, Ramanujam S, Wagner R, Witt P, Knight Jr E, Borden E. In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. Journal of immunology (Baltimore, Md: 1950). 1996; 157: 4100.
83. Knight E, Cordova B. IFN-induced 15-kDa protein is released from human lymphocytes and monocytes. The Journal of immunology. 1991; 146: 2280-2284.
84. Durfee LA, Lyon N, Seo K, Huibregtse JM. The ISG15 conjugation system broadly targets newly synthesized proteins: implications for the antiviral function of ISG15. Mol Cell. 2010; 38: 722-732. doi: 10.1016/j. molcel.2010.05.002.
85. Duitman E, Orinska Z, Bulfone-Paus S. Mechanisms of cytokine secretion: a portfolio of distinct pathways allows flexibility in cytokine activity. European journal of cell biology. 2011; 90: 476.
86. Merbl Y, Refour P, Patel H, Springer M, Kirschner MW. Profiling of ubiquitin-like modifications reveals features of mitotic control. Cell. 2013; 152: 1160.
87. Fan J-B, Arimoto K-l, Motamedchaboki K, Yan M, Wolf DA, Zhang D-E. Identification and characterization of a novel ISG15-ubiquitin mixed chain and its role in regulating protein homeostasis. Scientific Reports. 2015; 5.
88. Pitha-Rowe IF, Pitha PM. Viral defense, carcinogenesis and ISG15: novel roles for an old ISG. Cytokine Growth Factor Rev. 2007; 18: 409-417. doi: 10.1016/j. cytogfr.2007.06.017.
89. Zhao C, Denison C, Huibregtse JM, Gygi S, Krug RM. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc Natl Acad Sci U S A. 2005; 102: 10200-10205. doi: 10.1073/pnas.0504754102.
90. Shi H-X, Yang K, Liu X, Liu X-Y, Wei B, Shan Y-F, Zhu L-H, Wang C. Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. Molecular and cellular biology. 2010; 30: 2424-2436.
91. Saitoh T, Tun-Kyi A, Ryo A, Yamamoto M, Finn G, Fujita T, Akira S, Yamamoto N, Lu KP, Yamaoka S. Negative regulation of interferon-regulatory factor 3-dependent innate antiviral response by the prolyl isomerase Pin1. Nature immunology. 2006; 7: 598-605.
92. Nielsch U, Pine R, Zimmer S, Babiss L. Induced expression of the endogenous beta interferon gene in adenovirus type 5-transformed rat fibroblasts. Journal of virology. 1992; 66: 1884-1890.
93. Hsiang T-Y, Zhao C, Krug RM. Interferon-induced ISG15 conjugation inhibits influenza A virus gene expression and replication in human cells. Journal of virology. 2009; 83: 5971-5977.
94. Morales DJ, Lenschow DJ. The antiviral activities of ISG15. J Mol Biol. 2013; 425: 4995-5008. doi: 10.1016/j. jmb.2013.09.041.
95. Broering R, Zhang X, Kottilil S, Trippler M, Jiang M, Lu M, Gerken G, Schlaak JF. The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response. Gut. 2010; 59: 1111-1119. doi: 10.1136/gut.2009.195545.
96. Chen L, Sun J, Meng L, Heathcote J, Edwards AM, McGilvray ID. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. Journal of General Virology. 2010; 91: 382-388.
97. Zhang X, Bogunovic D, Payelle-Brogard B, Francois-Newton V, Speer SD, Yuan C, Volpi S, Li Z, Sanal O, Mansouri D, Tezcan I, Rice GI, Chen C, et al. Human intracellular ISG15 prevents interferon-alpha/beta overamplification and auto-inflammation. Nature. 2015; 517: 89-93. doi: 10.1038/nature13801.
98. Detjen K, Farwig K, Welzel M, Wiedenmann B, Rosewicz S. Interferon ? inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut. 2001; 49: 251.
99. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. The Journal of experimental medicine. 1999; 189: 1451-1460.
100. McMasters KM, Egger ME, Edwards MJ, Ross MI, Reintgen DS, Noyes RD, Martin RC, Goydos JS, Beitsch PD, Urist MM. Final results of the Sunbelt Melanoma Trial: a multi-institutional prospective randomized phase III study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy. Journal of Clinical Oncology. 2016: JCO633776.
101. Miamen AG, Dong H, Roberts LR. Immunotherapeutic approaches to hepatocellular carcinoma treatment. Liver Cancer. 2012; 1: 226-237. doi: 10.1159/000343837.
102. Ohwada S, Kobayashi I, Maemura M, Satoh Y, Ogawa T, Iino Y, Morishita Y. Interferon potentiates antiproliferative activity of CPT-11 against human colon cancer xenografts. Cancer letters. 1996; 110: 149.
103. Wang L, Jia D, Duan F, Sun Z, Liu X, Zhou L, Sun L, Ren S, Ruan Y, Gu J. Combined anti-tumor effects of IFN-a and sorafenib on hepatocellular carcinoma in vitro and in vivo. Biochemical and biophysical research communications. 2012; 422: 687.
104. Liang KC, Suzuki Y, Kumagai Y, Nakai K. Analysis of changes in transcription start site distribution by a classification approach. Gene. 2014; 537: 29-40. doi: 10.1016/j.gene.2013.12.038.
105. Padovan E, Terracciano L, Certa U, Jacobs B, Reschner A, Bolli M, Spagnoli GC, Borden EC, Heberer M. Interferon stimulated gene 15 constitutively produced by melanoma cells induces e-cadherin expression on human dendritic cells. Cancer Res. 2002; 62: 3453-3458.
106. Ishii K, Kurita-Taniguchi M, Aoki M, Kimura T, Kashiwazaki Y, Matsumoto M, Seya T. Gene-inducing program of human dendritic cells in response to BCG cellwall skeleton (CWS), which reflects adjuvancy required for tumor immunotherapy. Immunol Lett. 2005; 98: 280-290. doi: 10.1016/j.imlet.2004.12.002.
107. Desai SD, Haas AL, Wood LM, Tsai YC, Pestka S, Rubin EH, Saleem A, Nur EKA, Liu LF. Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. Cancer Res. 2006; 66: 921-928. doi: 10.1158/0008-5472.CAN-05-1123.
108. Laljee RP, Muddaiah S, Salagundi B, Cariappa PM, Indra AS, Sanjay V, Ramanathan A. Interferon stimulated gene-ISG15 is a potential diagnostic biomarker in oral squamous cell carcinomas. Asian Pac J Cancer Prev. 2013; 14: 1147-1150.
109. Chi L-M, Lee C-W, Chang K-P, Hao S-P, Lee H-M, Liang Y, Hsueh C, Yu C-J, Lee I-N, Chang Y-J. Enhanced Interferon Signaling Pathway in Oral Cancer Revealed by Quantitative Proteome Analysis of Microdissected Specimens Using 16O/18O Labeling and Integrated Twodimensional LC-ESI-MALDI Tandem MS. Molecular & Cellular Proteomics. 2009; 8: 1453.
110. Bektas N, Noetzel E, Veeck J, Press MF, Kristiansen G, Naami A, Hartmann A, Dimmler A, Beckmann MW, Knüchel R. The ubiquitin-like molecule interferonstimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Research. 2008; 10: R58.
111. Andersen JB, Aaboe M, Borden EC, Goloubeva OG, Hassel BA, Orntoft TF. Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer. 2006; 94: 1465-1471. doi: 10.1038/sj.bjc.6603099.
112. Jeon YJ, Jo MG, Yoo HM, Hong SH, Park JM, Ka SH, Oh KH, Seol JH, Jung YK, Chung CH. Chemosensitivity is controlled by p63 modification with ubiquitin-like protein ISG15. J Clin Invest. 2012; 122: 2622-2636. doi: 10.1172/JCI61762.
113. Burks J, Reed RE, Desai SD. Free ISG15 triggers an antitumor immune response against breast cancer: a new perspective. Oncotarget. 2015; 6: 7221-7231. doi: 10.18632/oncotarget.3372.
114. McLaughlin P, Helfrich W, Kok K, Mulder M, Hu S, Brinker M, Ruiters M, de Leij L, Buys C. The ubiquitinactivating enzyme E1-like protein in lung cancer cell lines. International journal of cancer. 2000; 85: 871.
115. Yin X, Cong X, Yan M, Zhang D. Deficiency of a potential 3p21. 3 tumor suppressor gene UBE1L (UBA7) does not accelerate lung cancer development in K-rasLA2 mice. Lung cancer (Amsterdam, Netherlands). 2009; 63: 194.
116. Yin X, Cong X, Yan M, Zhang D. Alteration of tumor spectrum by ISGylation in p53-deficient mice. Cancer biology & therapy. 2009; 8: 1167.
117. Parlato S, Santini S, Lapenta C, Di Pucchio T, Logozzi M, Spada M, Giammarioli A, Malorni W, Fais S, Belardelli F. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood. 2001; 98: 3022.
118. Landolfo S, Guarini A, Riera L, Gariglio M, Gribaudo G, Cignetti A, Cordone I, Montefusco E, Mandelli F, Foa R. Chronic myeloid leukemia cells resistant to interferon-alpha lack STAT1 expression. The hematology journal. 2000; 1: 7.
119. Akyerli C, Beksac M, Holko M, Frevel M, Dalva K, Ozbek U, Soydan E, Ozcan M, Ozet G, Ilhan O. Expression of IFITM1 in chronic myeloid leukemia patients. Leukemia research. 2005; 29: 283.
120. Zimmer R, Thomas P. Expression profiling and interferonbeta regulation of liver metastases in colorectal cancer cells. Clinical & experimental metastasis. 2002; 19: 541.
121. Cabrera C, Jiménez P, Cabrera T, Esparza C, Ruiz-Cabello F, Garrido F. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue antigens. 2003; 61: 211.
122. Seth A, Kitching R, Landberg G, Xu J, Zubovits J, Burger A. Gene expression profiling of ductal carcinomas in situ and invasive breast tumors. Anticancer research. 2003; 23: 2043.
123. Shou J, Soriano R, Hayward SW, Cunha GR, Williams PM, Gao W-Q. Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99: 2830.
124. Hoek K, Rimm D, Williams K, Zhao H, Ariyan S, Lin A, Kluger H, Berger A, Cheng E, Trombetta E. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer research. 2004; 64: 5270.
125. Lu R, Au W, Yeow W, Hageman N, Pitha P. Regulation of the promoter activity of interferon regulatory factor-7 gene. Activation by interferon snd silencing by hypermethylation. The Journal of biological chemistry. 2000; 275: 31805.
126. Kulaeva O, Draghici S, Tang L, Kraniak J, Land S, Tainsky M. Epigenetic silencing of multiple interferon pathway genes after cellular immortalization. Oncogene. 2003; 22: 4118.
127. Karpf AR, Peterson PW, Rawlins JT, Dalley BK, Yang Q, Albertsen H, Jones DA. Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96: 14007.
128. Reu F, Bae S, Cherkassky L, Leaman D, Lindner D, Beaulieu N, MacLeod A, Borden E. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. Journal of clinical oncology. 2006; 24: 3771.
129. Katzenellenbogen R, Baylin S, Herman J. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood. 1999; 93: 4347.
130. Cunningham D, Chua YJ. East meets west in the treatment of gastric cancer. N Engl J Med. 2007; 357: 1863-1865. doi: 10.1056/NEJMe078182.
131. Kim ST, Sohn I, Do IG, Jang J, Kim SH, Jung IH, Park JO, Park YS, Talasaz A, Lee J, Kim HC. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer. Cancer Genomics Proteomics. 2014; 11: 259-266. doi:
132. Fan ST, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK, Ming Lam C, Ng KK, Ching Chan S. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg. 2011; 253: 745-758. doi: 10.1097/SLA.0b013e3182111195.
133. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96. doi: 10.3322/CA.2007.0010.
134. Stelzner F, Ruhlmann J, von Mallek D. [Prediction of prognosis of pancreatic cancer based on the homing area]. Chirurg. 2013; 84: 214, 216-221. doi: 10.1007/s00104-012-2301-2.
135. Shen J, Wei J, Wang H, Yue G, Yu L, Yang Y, Xie L, Zou Z, Qian X, Ding Y, Guan W, Liu B. A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer. J Transl Med. 2013; 11: 73. doi: 10.1186/1479-5876-11-73.
136. Li C, Wang J, Zhang H, Zhu M, Chen F, Hu Y, Liu H, Zhu H. Interferon-stimulated gene 15 (ISG15) is a trigger for tumorigenesis and metastasis of hepatocellular carcinoma. Oncotarget. 2014; 5: 8429-8441. doi: 10.18632/oncotarget.2316.
137. Chen M, Lee K, Lu M, Chen C, Hsieh M, Liu Y, Lin P, Chen W. The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma. Journal of molecular medicine (Berlin, Germany). 2009; 87: 307.
138. Yan W, Shih JH, Rodriguez-Canales J, Tangrea MA, Ylaya K, Hipp J, Player A, Hu N, Goldstein AM, Taylor PR. Identification of unique expression signatures and therapeutic targets in esophageal squamous cell carcinoma. BMC Research Notes. 2012; 5: 73.
139. Tao J, Hua P, Wen J, Hu Y, Yang H, Xie X. Prognostic value of ISG15 mRNA level in drinkers with esophageal squamous cell cancers. International journal of clinical and experimental pathology. 2015; 8: 10975.
140. Talvinen K, Tuikkala J, Grönroos J, Huhtinen H, Kronqvist P, Aittokallio T, Nevalainen O, Hiekkanen H, Nevalainen T, Sundström J. Biochemical and clinical approaches in evaluating the prognosis of colon cancer. Anticancer research. 2006; 26: 4745.
141. Ina S, Hirono S, Noda T, Yamaue H. Identifying molecular markers for chemosensitivity to gemcitabine in pancreatic cancer: increased expression of interferon-stimulated gene 15 kd is associated with intrinsic chemoresistance. Pancreas. 2010; 39: 473-485. doi: 10.1097/MPA.0b013e3181c0decc.
142. Yang S, Jeung H, Jeong H, Choi Y, Kim J, Jung J, Rha S, Yang W, Chung H. Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer. Genomics. 2007; 89: 451.
143. Lee J, Li L, Gretz N, Gebert J, Dihlmann S. Absent in Melanoma 2 (AIM2) is an important mediator of interferondependent and-independent HLA-DRA and HLA-DRB gene expression in colorectal cancers. Oncogene. 2012; 31: 1242-1253. doi: 10.1038/onc.2011.320.
144. Künzli B, Berberat P, Zhu Z, Martignoni M, Kleeff J, Tempia-Caliera A, Fukuda M, Zimmermann A, Friess H, Büchler M. Influences of the lysosomal associated membrane proteins (Lamp-1, Lamp-2) and Mac-2 binding protein (Mac-2-BP) on the prognosis of pancreatic carcinoma. Cancer. 2002; 94: 228.
145. Park Y, Choi S, Kim J, Song E, Kim J, Yoon D, Yeom Y, Lim J, Kim J, Paik S. Up-regulation of Mac-2 binding protein by hTERT in gastric cancer. International journal of cancer. 2006; 120: 813.
146. Wu CC, Huang YS, Lee LY, Liang Y, Tang RP, Chang YS, Hsieh LL, Yu JS. Overexpression and elevated plasma level of tumor-associated antigen 90K/Mac-2 binding protein in colorectal carcinoma. Proteomics Clin Appl. 2008; 2: 1586-1595. doi: 10.1002/prca.200800080.
147. Wu K-L, Chen H-H, Pen C-T, Yeh W-L, Huang E-Y, Hsiao C-C, Yang KD. Circulating Galectin-1 and 90K/Mac-2BP Correlated with the Tumor Stages of Patients with Colorectal Cancer. BioMed Research International. 2015; 2015.
148. Lee JH, Bae JA, Lee JH, Seo YW, Kho DH, Sun EG, Lee SE, Cho SH, Joo YE, Ahn KY, Chung IJ, Kim KK. Glycoprotein 90K, downregulated in advanced colorectal cancer tissues, interacts with CD9/CD82 and suppresses the Wnt/beta-catenin signal via ISGylation of beta-catenin. Gut. 2010; 59: 907-917. doi: 10.1136/gut.2009.194068.
149. O'Brien C, Pollett A, Gallinger S, Dick J. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007; 445: 106.
150. Ricci-Vitiani L, Lombardi D, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007; 445: 111.
151. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. nature. 2004; 432: 396-401.
152. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, Clair RS, Baljevic M, White I, Jin DK. CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. The Journal of Clinical Investigation. 2008; 118: 2111.
153. Hou J, Zhou Y, Zheng Y, Fan J, Zhou W, Ng IO, Sun H, Qin L, Qiu S, Lee JM, Lo CM, Man K, Yang Y, et al. Hepatic RIG-I predicts survival and interferon-alpha therapeutic response in hepatocellular carcinoma. Cancer Cell. 2014; 25: 49-63. doi: 10.1016/j.ccr.2013.11.011.
154. Qiu X, Hong Y, Yang D, Xia M, Zhu H, Li Q, Xie H, Wu Q, Liu C, Zuo C. ISG15 as a novel prognostic biomarker for hepatitis B virus-related hepatocellular carcinoma. Int J Clin Exp Med. 2015; 8: 17140-17150.
155. Konishi H, Shirabe K, Yoshiya S, Ikeda T, Ikegami T, Yoshizumi T, Ikawa-Yoshida A, Motomura T, Fukuhara T, Maehara Y. Hepatic interferon-gamma-induced protein-10 expression is more strongly associated with liver fibrosis than interleukin-28B single nucleotide polymorphisms in hepatocellular carcinoma resected patients with chronic hepatitis C. Hepatol Res. 2013; 43: 1139-1147. doi: 10.1111/hepr.12070.
156. Wan XX, Chen HC, Khan MA, Xu AH, Yang FL, Zhang YY, Zhang DZ. ISG15 inhibits IFN-alpha-resistant liver cancer cell growth. Biomed Res Int. 2013; 2013: 570909. doi: 10.1155/2013/570909.
157. Sainz B, Jr., Martin B, Tatari M, Heeschen C, Guerra S. ISG15 is a critical microenvironmental factor for pancreatic cancer stem cells. Cancer Res. 2014; 74: 7309-7320. doi: 10.1158/0008-5472.CAN-14-1354.
158. Pitha-Rowe I, Hassel B, Dmitrovsky E. Involvement of UBE1L in ISG15 conjugation during retinoid-induced differentiation of acute promyelocytic leukemia. The Journal of biological chemistry. 2004; 279: 18178.
159. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, Su AW, Shaikh AY, Roach P, Kreike B. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proceedings of the National Academy of Sciences. 2008; 105: 18490-18495.
160. Liu M, Hummer B, Li X, Hassel B. Camptothecin induces the ubiquitin-like protein, ISG15, and enhances ISG15 conjugation in response to interferon. Journal of interferon & cytokine research. 2004; 24: 647-654.
161. Matsumura Y, Yashiro M, Ohira M, Tabuchi H, Hirakawa K. 5-Fluorouracil up-regulates interferon pathway gene expression in esophageal cancer cells. Anticancer Res. 2005; 25: 3271-3278.
162. Chun J, Kim H, Kim E, Kim I, Kim J, Chang H, Choi I, Lim H, Kim I, Kang H. Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer. Cancer research. 2004; 64: 4703.
163. Yao Y, Richman L, Morehouse C, de los Reyes M, Higgs BW, Boutrin A, White B, Coyle A, Krueger J, Kiener PA, Jallal B. Type I interferon: potential therapeutic target for psoriasis? PLoS One. 2008; 3: e2737. doi: 10.1371/journal. pone.0002737.
164. Roulois D, Loo YH, Singhania R, Wang Y, Danesh A, Shen S, Han H, Liang G, Jones P, Pugh T. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell. 2015; 162: 961.
165. Skaug B, Chen ZJ. Emerging role of ISG15 in antiviral immunity. Cell. 2010; 143: 187-190. doi: 10.1016/j. cell.2010.09.033.